StockData

Kazia Therapeutics vs Moleculin Biotech

KZIA and MBRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KZIA and MBRX compare

Moleculin Biotech scores higher on the StockData Score (4 against 1 for Kazia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKZIAMBRX
Size and price
Market cap–$133M
Share price$5.31$6.83
Change, 1 year−15.3%−96.9%
Change, 5 years−98.9%−100.0%
Beta (5Y)4.08−1.10
Employees14150K
StockData Score
Total score14 (better)
Valuation score00
Growth score00
Performance score00
Health score14 (better)
Dividend score00
Valuation
P/B–11.5×
Growth
Revenue growth (TTM)−98.2%–
Profitability
Net margin−49291%–
Return on equity–−524%
Financial health
Debt / equity–0.00
Current ratio2.87 (better)0.94
Altman Z-score–−11.19
Piotroski F-score23 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.45%0.05%
Held by insiders0.29%20.2%
Superinvestors holding1–
Short interest, % of float–0.35%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.